In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves 'broad range' of patient-reported outcomes and more. Read the full coverage here: FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis Deucravacitinib improves 'broad range' of patient-reported psoriatic arthritis outcomes Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA References: Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716. Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531. Press Release Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8. Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.

Ver todos los episodios